Objective: To establish a method for related substances determination in timolol maleate by ultra-high performance liquid chromatography-quadrupole/orbitrap high resolution mass spectrometry(UPLC-Q/Orbitrap HRMS), by which the impurities both in active pharmaceutical ingredients(APIs) and preparations can be recognized and determined. Methods: An ACE Excel3 C18-AR column(150 mm×4.6 mm, 3 μm)was used for the separation and a mixture of 0.01 mol·L-1 ammonium acetate solution with 0.02% formic acid and methanol was employed as the mobile phase by gradient elution, at a flow rate of 0.6 mL·min-1. The detection wavelength for UV detector was 295 nm, an HESI(heated ESI)ion source was employed in both the positive mode and negative mode. The possible fragmentation patterns prediction was conducted with the help of Mass Frontier 8.0 and Compound Discover 3.3. The related substances could be recognized and determined by means of the forced degradation of the APIs, with the calibration by the correction factors and confirmation by the mass spectrum data from UPLC-Q/Orbitrap HRMS. Results: The timolol impurity B[3-(tert-butylamino)-2-(4-morpholino-1, 2, 5-thiadiazol-3-yloxy)propan-1-ol], timolol impurity D(4-morpholino-1,2,5-thiadiazol-2-ol), timolol impurity E((S,Z)-4-(｛1-(tert-butylamino)- 3-[(4-morpholino-1, 2, 5-thiadiazol-3-yl) oxy] propan-2-yl｝oxy)-4-oxobut-2-enoic acid maleate salt) and timolol impurity C[N-(tert-butyl)-2, 3-bis (4-morphloline-1, 2, 5-thiadiazol-3-yloxy) propan-1-amine maleate] were produced from the APIs under selected conditions and separated well in the specified HPLC condition, the limit of quantitation was 0.05 μg·mL-1 and the limit of detection was 0.015 μg·mL-1 for HPLC-UV. The contents of individual impurities were between 0.000 4%-0.09% and the results of total impurities were between 0.02%-0.12% for the samples from 4 different manufactures. The probable chemical structures of the 6 unspecified impurities were speculated according to the fragmentation pattern of fragment ions, combined with the fragment information, chemical structure of API and the references. Conclusion: The system solution can be obtained by the degradation of the API, and be implied in the impurity analysis for the timolol maleate. The results can be used as a reference for the quality control of timolol maletae.
TIAN Heng, WU Chun-min, YAN Quan-hong
. Identification and determination of related substances of timolol maleate*[J]. Chinese Journal of Pharmaceutical Analysis, 2024
, 44(3)
: 450
-461
.
DOI: 10.16155/j.0254-1793.2024.03.10
[1] MAZZO DJ, LOPER AE. Timolol maleate[J]. Anal Profiles Drug Subst, 1987, 16: 641
[2] 国家药典委员会. 中华人民共和国药典临床用药须知[M]. 2020年版. 北京: 中国医药科技出版社, 2022: 328
Chinese Pharmacopoeia Commission. Ch.P Clinical Medication instruction[M]. 2020 Ed. Beijing: Chinese Medical Science Press, 2017: 245
[3] 中华人民共和国药典 2020年版. 二部[S]. 2020: 73
ChP 2020. Vol Ⅱ[S]. 2020: 73
[4] USP-NF [S/OL]. Official as of 01-May-2020. DOI:https://doi.org/10.31003/USPNF_M83650_06_01
[5] BP 2023 [S]. 2023:1164
[6] 贺美莲, 郭常川, 石峰, 等. Orbitrap高分辨质谱技术在药物分析领域中的应用进展[J]. 药物分析杂志, 2019, 39(1): 105
HE ML, GUO CC, SHI F, et al. Application progress of Orbitrap high resolution mass spectrometry in the field of pharmaceutical analysis[J]. Chin J Pharm Anal, 2019, 39(1): 105
[7] 杨彦涛, 李卓伦, 王松, 等. UHPLC-Q-Orbitrap HRMS法鉴定盐酸阿扎司琼中的有关物质[J]. 药物分析杂志, 2019, 39(9): 1625
YANG YT, LI ZL, WANG S, et al. Identification of related substances in azasetron hydrochloride by UHPLC-Q-Orbitrap HRMS[J]. Chin J Pharm Anal, 2019, 39(9): 1625
[8] 国家药典委员会. 中华人民共和国药典二部注释[M]. 2015年版. 北京: 中国医药科技出版社,2019: 61
Chinese Pharmacopoeia Commission. ChP Vol. Ⅱ Notes[M]. 2015 Ed. Beijing: Chinese Medical Science Press, 2019: 61
[9] 刘荷英, 程奇珍, 周敏, 等. 马来酸噻吗洛尔滴眼液中有关物质的测定及杂质定性研究[J]. 中国药房, 2018, 29(16): 2208
LIU HY, CHENG QZ, ZHOU M, et al. Determination of related substance and impurities qualitative study of timolol maleate eye drops[J]. China Pharm, 2018, 29(16): 2208
[10] DEVRUKHAKAR PS, SHANKAR MS, SHANKAR G, et al. Proposal of degradation pathway with toxicity prediction for hydrolytic and photolytic degradation products of timolol[J]. J Pharm Biomed Anal, 2018, 154: 7
[11] CHEN Y, LIANG Q, ZHOU D, et al. Photodegradation Kinetics, products and mechanism of timolol under simulated sunlight[J]. J Hazard Mater, 2013, 252-253: 220
[12] MAZZO DJ, SNYDER PA. High-performance liquid chromatography of timolol and potential degradates on dynamically modified silica[J]. J Chromatogr, 1988, 438(1): 85
[13] VOLOTINEN M, HAKKOLA J, PELKONEN O, et al. Metabolism of ophthalmic timolol: new aspects of an old drug[J]. Basic Clin Pharm Toxicol, 2011, 108(5): 297
[14] LACROIX M, DAWSON BA, SEARS RW, et al. HPLC and NMR methods for the quantitation of the (R)-enantiomer in -(S)-timolol maleate drug raw materials[J]. Chirality, 1994, 6(6): 484
[15] CHEN Y, WILLIS MC. An aryne-based route to substituted benzoisothiazoles[J]. Org Lett, 2015, 17(19): 4786
[16] VOLOTINEN M, KORJAMO T, TOLONEN A, et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes[J]. Basic Clin Pharm Toxicol, 2010, 106(4): 302
